- Home
- KURA vs PDFS Comparison
KURA vs PDFS Comparison
Compare KURA & PDFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- PDFS
- Stock Information
- Founded
- KURA 2014
- PDFS 1992
- Country
- KURA United States
- PDFS United States
- Employees
- KURA N/A
- PDFS N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- PDFS EDP Services
- Sector
- KURA Health Care
- PDFS Technology
- Exchange
- KURA Nasdaq
- PDFS Nasdaq
- Market Cap
- KURA 1.5B
- PDFS N/A
- IPO Year
- KURA N/A
- PDFS N/A
- Fundamental
- Price
- KURA $19.95
- PDFS $28.84
- Analyst Decision
- KURA Strong Buy
- PDFS Strong Buy
- Analyst Count
- KURA 6
- PDFS 2
- Target Price
- KURA $30.60
- PDFS $41.00
- AVG Volume (30 Days)
- KURA 389.9K
- PDFS 142.8K
- Earning Date
- KURA 10-31-2024
- PDFS 11-06-2024
- Dividend Yield
- KURA N/A
- PDFS N/A
- EPS Growth
- KURA N/A
- PDFS N/A
- EPS
- KURA N/A
- PDFS N/A
- Revenue
- KURA N/A
- PDFS $166,446,000.00
- Revenue This Year
- KURA N/A
- PDFS $11.58
- Revenue Next Year
- KURA N/A
- PDFS $24.43
- P/E Ratio
- KURA N/A
- PDFS N/A
- Revenue Growth
- KURA N/A
- PDFS 2.28
- 52 Week Low
- KURA $7.41
- PDFS $26.12
- 52 Week High
- KURA $24.17
- PDFS $39.70
- Technical
- Relative Strength Index (RSI)
- KURA 49.66
- PDFS 39.07
- Support Level
- KURA $19.26
- PDFS $27.81
- Resistance Level
- KURA $20.45
- PDFS $31.98
- Average True Range (ATR)
- KURA 0.71
- PDFS 0.87
- MACD
- KURA -0.01
- PDFS -0.10
- Stochastic Oscillator
- KURA 33.48
- PDFS 21.86
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.